ADTX Company Profile and Key Details

Q: Who are the executives of ADTX?

Dr. Dolly B. Tyan Ph.D.Senior Vice President of Clinical Devel. TransplantationMr. Amro A. AlbannaCo-Founder, Chairman & Chief Executive OfficerMs. Corinne D. Pankovcin CPA, CPA, M.B.A.PresMr. Matthew M. ShatzkesChief Legal Officer & Gen. CounselMs. Rowena AlbannaChief Operating OfficerMr. Thomas J. Farley CPAChief Financial OfficerMs. Maureen ConnollyChief Content & Engagement OfficerMs. Corinne D. Pankovcin C.P.A., CPA, M.B.A.Chief Commercialization OfficerMr. Ge Chen M.D., M.S.Senior Vice President of Preclinical Research & DiscoveryDr. Shahrokh Shabahang D.D.S., M.S., Ph.D.Co-Founder, Chief Innovation Officer, Sec. & DirectorMr. Matthew M. Shatzkes Esq.Chief Legal Officer, Gen. Counsel & Corporation Sec.

NASDAQ : ADTX

Aditxt

$0.01

-0.0007-8.86%

At Close 4:00 PM

66.54

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Aditxt, Inc. (ADTX) stock declined over -11.39%, trading at $0.01 on OTC, down from the previous close of $0.01. The stock opened at $0.01, fluctuating between $0.01 and $0.01 in the recent session.

Stock Snapshot

0.0079

Prev. Close

6.99M

Market Cap

0.0065

Day Low

N/A

P/E Ratio

-40.751

EPS (TTM)

-14.1

Cash Flow per Share

0.01

Open

997.98M

Number of Shares

0.0083

Day High

100%

Free Float in %

12.17

Book Value

12.28M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 02, 2026	0.01	0.01	0.01	0.01	24.46M
Sep 01, 2026	0.01	0.01	0.01	0.01	19.73M
Aug 31, 2026	0.01	0.01	0.01	0.01	25.84M
Aug 28, 2026	0.01	0.01	0.01	0.01	44.2M
Aug 27, 2026	0.01	0.01	0.00	0.01	27.67M
Aug 26, 2026	0.01	0.01	0.00	0.01	40.38M
Aug 25, 2026	0.01	0.01	0.00	0.01	88.52M
Aug 24, 2026	0.01	0.01	0.00	0.01	127.27M
Aug 21, 2026	0.00	0.01	0.00	0.01	117.37M
Aug 20, 2026	0.00	0.00	0.00	0.00	10.33M
Aug 19, 2026	0.00	0.00	0.00	0.00	13.25M
Aug 18, 2026	0.00	0.00	0.00	0.00	0
Aug 17, 2026	0.00	0.00	0.00	0.00	7.98M
Aug 14, 2026	0.00	0.00	0.00	0.00	8.09M
Aug 13, 2026	0.00	0.00	0.00	0.00	0
Aug 12, 2026	0.00	0.00	0.00	0.00	9.7M
Aug 11, 2026	0.00	0.00	0.00	0.00	10.1M
Aug 10, 2026	0.00	0.00	0.00	0.00	8.42M
Aug 07, 2026	0.00	0.00	0.00	0.00	13.05M
Aug 06, 2026	0.00	0.00	0.00	0.00	8.87M

Contact Details

Mountain View, CA 94043

United States

https://www.aditxt.com 650 870 1200

About Company

Aditxt, Inc. is a biotechnology firm dedicated to advancing immune system health through innovative mapping and reprogramming techniques. The company's developments include AditxtScore, a platform designed to empower individuals by providing insights into their immune profiles for better management and informed awareness of immune system attacks or dysfunctions. Aditxt also pioneers Apoptotic DNA Immunotherapy, a nucleic acid-based solution that emulates the body's inherent mechanisms for developing self-tolerance to its own tissues. Additionally, Aditxt is actively researching and developing ADi products with diverse therapeutic applications, such as for organ transplant procedures (including skin grafting), various autoimmune conditions, and allergic reactions. The company holds licensing agreements with esteemed institutions like Loma Linda University and Leland Stanford Junior University. Established in 2017, this Richmond, Virginia-headquartered company was initially known as ADiTx Therapeutics, Inc. before rebranding to Aditxt, Inc. in July 2021.

Stock Peers

LZAGF

-5-0.92%

Lonza Group AG$541.00 GNMSF

Genmab A/S$268.61 CMXHF

CSL Limited$192.00 CSLLY

0.75+0.79%

CSL Limited$95.35 UCBJY

-0.06-0.08%

UCB SA$73.15 LZAGY

-0.33-0.61%

Lonza Group AG$53.87 PHMMF

4.3+16.01%

Pharma Mar, S.A.$31.15 BVNKF

Bavarian Nordic A/S$21.20 GRTX

1.53+9.80%

Galera Therapeutics, Inc.$17.15 NURPF

Neuren Pharmaceuticals Limited$14.00

Frequently Asked Questions

What is the current Aditxt, Inc. (ADTX) stock price?

Aditxt, Inc. (OTC: ADTX) stock price is $0.01 in the last trading session. During the trading session, ADTX stock reached the peak price of $0.01 while $0.01 was the lowest point it dropped to. The percentage change in ADTX stock occurred in the recent session was -11.39% while the dollar amount for the price change in ADTX stock was - $0.00.

ADTX's industry and sector of operation?

The OTC listed ADTX is part of Biotechnology industry that operates in the broader Healthcare sector. Aditxt, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ADTX?

Dr. Dolly B. Tyan Ph.D.
Senior Vice President of Clinical Devel. Transplantation
Mr. Amro A. Albanna
Co-Founder, Chairman & Chief Executive Officer
Ms. Corinne D. Pankovcin CPA, CPA, M.B.A.
Pres
Mr. Matthew M. Shatzkes
Chief Legal Officer & Gen. Counsel
Ms. Rowena Albanna
Chief Operating Officer
Mr. Thomas J. Farley CPA
Chief Financial Officer
Ms. Maureen Connolly
Chief Content & Engagement Officer
Ms. Corinne D. Pankovcin C.P.A., CPA, M.B.A.
Chief Commercialization Officer
Mr. Ge Chen M.D., M.S.
Senior Vice President of Preclinical Research & Discovery
Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D.
Co-Founder, Chief Innovation Officer, Sec. & Director
Mr. Matthew M. Shatzkes Esq.
Chief Legal Officer, Gen. Counsel & Corporation Sec.

How ADTX did perform over past 52-week?

ADTX's closing price is 260% higher than its 52-week low of $0.00 where as its distance from 52-week high of $27,092.88 is -100%.

How many employees does ADTX have?

Number of ADTX employees currently stands at 26.

Link for ADTX official website?

Official Website of ADTX is: https://www.aditxt.com

How do I contact ADTX?

ADTX could be contacted at phone 650 870 1200 and can also be accessed through its website. ADTX operates from 2569 Wyandotte Street, Mountain View, CA 94043, United States.

How many shares of ADTX are traded daily?

ADTX stock volume for the day was 12.28M shares. The average number of ADTX shares traded daily for last 3 months was 424.17M.

What is the market cap of ADTX currently?

The market value of ADTX currently stands at $6.99M with its latest stock price at $0.01 and 997.98M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	26
Beta	0.93
Sales or Revenue	$645.18K
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	26
Beta	0.93
Sales or Revenue	$645.18K
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ADTX Company Profile and Key Details

Aditxt

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Company Overview

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Valuation Metrics

Key Takeaways

Price Forecast & Outlook